%0 Journal Article
%T USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia
%A Daolin Tang
%A Hongbiao Huang
%A Jinbao Liu
%A Lili Jiang
%A Ningning Liu
%A Ruiqing Zhou
%A Xiaohong Xia
%A Yanling Li
%A Yuning Liao
%A Zhiqiang Guo
%J Archive of "Cell Discovery".
%D 2019
%R 10.1038/s41421-019-0092-z
%X a Cell viability of CML cells post Imatinib (IM) treatment for the indicated times. b Western blot analysis for the indicated proteins in CML cells exposed to IM for 24£¿h. c Western blot analysis and Co-IP analysis for the indicated proteins in CML cells. d, e Western blot assay for the indicated proteins in CML cells exposed to specific inhibitor of SKP2 (SKP2-C25) or stably expressing SKP2 shRNA. f, g Cell viability of CML cells exposed to SKP2-C25 for 48£¿h or stably expressing SKP2 shRNA/control shRNA for 24, 48, and 72£¿h. Error bars correspond to 95% confidence intervals of three independent experiments. *P£¿<£¿0.05 versus each vehicle control. h Western blot and Co-IP assays to detect K63/K48-linked ubiquitination of Bcr-Abl of KBM5-T315I cells post SKP2 shRNA/SKP2-C25 treatmen
%K Chronic myeloid leukaemia
%K Drug development
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488640/